Motus Therapeutics, Inc.
7
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
1 terminated/withdrawn out of 7 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa
Role: lead
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
Role: lead
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation
Role: lead
Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation
Role: lead
Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation
Role: lead
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
Role: lead
Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers
Role: lead
All 7 trials loaded